Advertisement
Research Article|Articles in Press, 100472

Sleeve lobectomy after neoadjuvant chemoimmunotherapy versus chemotherapy for squamous cell lung cancer: a multicenter, retrospective study

Open AccessPublished:February 01, 2023DOI:https://doi.org/10.1016/j.jtocrr.2023.100472
Sleeve lobectomy after neoadjuvant chemoimmunotherapy versus chemotherapy for squamous cell lung cancer: a multicenter, retrospective study
Previous ArticleFirst-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Japanese subgroup analysis of CROWN
      This paper is only available as a PDF. To read, Please Download here.

      ABSTRACT

      Objective

      To analyze the feasibility and efficacy of sleeve lobectomy after neoadjuvant immunotherapy in multicenter patients with squamous cell lung cancer.

      Methods

      We retrospectively identified patients who received neoadjuvant immunotherapy (n = 14) or chemotherapy alone (n = 33) at 5 thoracic-surgery centers between 2018 and 2020. The primary endpoint was 30-day major complications. The secondary endpoint was major pathological response. Multivariate analysis was performed with a log-binomial regression model adjusting potential risk factors.

      Results

      All patients received induction therapy and underwent sleeve lobectomy without 90-day postoperative deaths. The distribution of age, sex, nutrition status, pulmonary and cardiac function, tumor stage, surgical approach, and location of pulmonary lobe were well balanced between two cohorts. In immunotherapy cohort, 2 patients (14.3%) experienced a pulmonary major complication, whereas 9 pulmonary major complications and 1 cardiac major complication (30.3%) occurred in chemotherapy cohort patients (p = .302).

      Conclusion

      Neoadjuvant immunotherapy in addition to chemotherapy did not increase 30-day risk of postoperative complications, and immunotherapy is a favorable factor affecting pathological downstage and response. Therefore, sleeve lobectomy after induction chemoimmunotherapy is safe and feasible.

      Keywords

      Glossary of Abbreviations:

      NSCLC (non-small cell lung cancer), ICI (immune checkpoint inhibitor), CT (computed tomography), PET (positron emission tomography), MPR (major pathological response), pCR (pathological complete response)

      Article info

      Publication history

      Accepted: January 24, 2023
      Received in revised form: January 4, 2023
      Received: June 13, 2022

      Publication stage

      In Press Journal Pre-Proof

      Footnotes

      Source of Funding: This work was supported by National Natural Science Foundation of China (Grant No.82272679, No.81972176), Shanghai Science and Technology Committee (18411966100), Shanghai Talent Development Fund (2019073), Shanghai Natural Science Foundation (Grant No.18ZR1435100), Shanghai Rising Stars of Medical Talent, Youth Development Program (Specialist Program), Morningstar award program for outstanding young scholars of Shanghai Jiao Tong University.

      Institutional Review Board (IRB) number: IS22011, January 25, 2022.

      Disclosure: The authors declare no potential conflicts of interest.

      Data Availability Statement: The data underlying this article will be shared on reasonable request to the corresponding author.

      CRediT author statement: Tianxiang Chen: Conceptualization, Resources, Writing - Review & Editing. Junwei Ning: Writing - Original Draft, Software, Methodology. Jianfei Shen: Investigation,Data Curation. Hui Pan: Investigation,Data Curation. Linhai Fu: Investigation,Data Curation. Enwu Xu: Investigation,Data Curation. Han Wu: Investigation,Data Curation. Jia Huang: Investigation,Data Curation. Yunhai Yang: Investigation,Data Curation. Ziming Li: Investigation,Data Curation. Qingquan Luo: Project administration, Funding acquisition, Resources.

      Tianxiang Chen: Conceptualization, Methodology, Writing- Reviewing and Editing. Junwei Ning: Data curation, Writing- Original draft preparation, Software, Visualization. Jianfei Shen: Resources, Investigation. Hui Pan: Resources, Investigation. Linhai Fu: Resources, Investigation. Enwu Xu: Resources, Investigation. Han Wu: Validation. Jia Huang: Supervision. Yunhai Yang: Resources, Supervision. Qingquan Luo: Writing- Reviewing and Editing, Funding acquisition.

      Identification

      DOI: https://doi.org/10.1016/j.jtocrr.2023.100472

      Copyright

      © 2023 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX